Abstract
Purpose :
To compare the add-on effect of brimonidine 0.1% on intraocular pressure (IOP) in patients with secondary glaucoma (SG) to those of primary open angle glaucoma (POAG).
Methods :
Medical records of 245 eyes of 161 patients who received brimonidine tartrate 0.1% ophthalmic solution in addition to other antiglaucoma eye drops were retrospectively reviewed. The age (mean ± standard deviation) was 69.0 ± 12.2 years, and 90 patients (55.9%) were men. Of 245 eyes, 152 eyes were POAG, 42 eyes were neovascular glaucoma (NVG), and 51 eyes were uveitis-associated glaucoma (UG) in which 28 eyes were inflammatory glaucoma (UIG) and 23 eyes were steroid glaucoma (USG). Preceding antiglaucoma eye drops, and IOP at the initiation of brimonidine 0.1% treatment and at the last visit were extracted. IOP reduction and the reduction rates by add-on brimonidine 0.1% were compared between POAG, NVG, UIG, and USG.
Results :
The follow-up period (mean ± standard deviation) was 18.5 ± 6.8 months in total, 21.4 ± 5.5 months in POAG group, 15.7 ± 6.4 months in UIG group, 16.9 ± 7.6 months in USG group, and 16.6 ± 5.7 months in NVG group. The age was highest in POAG group (71.0 ± 10.4), followed by UIG (70.4 ± 7.5), USG (61.7 ± 13.8), and NVG (59.4 ± 16.6), however there was no statistical difference between them. IOP was significantly reduced in all groups by add-on brimonidine 0.1%, and IOP reduction was from 20.1 ± 8.6 to 15.7 ± 6.6 mmHg (-4.4 mmHg) in total, from 15.9 ± 4.4 to 13.5 ± 3.6 mmHg (-2.4 mmHg) in POAG group, from 26.6 ± 10.0 to 18.6 ± 7.2 mmHg (-8.0 mmHg) in UIG group, from 27.0 ± 7.1 to 15.6 ± 3.5 mmHg (-11.4 mmHg) in USG group, and from 29.4 ± 12.6 to 24.2 ± 12.7 mmHg (-5.2 mmHg) in NVG group. IOP reduction was significantly higher in UIG and USG groups compared with POAG group. IOP reduction rates were 18.0 ± 20.9% in total, 13.5 ± 16.2% in POAG group, 27.1 ± 17.4% in UIG group, 38.2 ± 22.1% in USG group, and 14.8 ± 33.1% in NVG group, and there was significant difference between USG and POAG groups. IOP reduction or IOP reduction rates were not affected by preceding antiglaucoma eye drops or the combinations.
Conclusions :
These results indicate that IOP reduction was achieved in NVG and UG by add-on brimonidine 0.1%, and the IOP reduction was preferentially effective for UG compared with POAG.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.